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SUMMARY
Tuberculosis is one of the most frequent opportunistic infections after renal transplantation and occurred in 30 of 1264 patients
transplanted between 1976 and 1996 at Hospital São Paulo – UNIFESP and Hospital Dom Silvério, Brazil. The incidence of 2.4% is
five times higher than the Brazilian general population. The disease occurred between 50 days to 18 years after the transplant, and had
an earlier and worse development in patients receiving azathioprine, prednisone and cyclosporine, with 35% presenting as a disseminated
disease, while all patients receiving azathioprine and prednisone had exclusively pulmonary disease. Ninety percent of those patients
had fever as the major initial clinical manifestation. Diagnosis was made by biopsy of the lesion (50%), positivity to M. tuberculosis
in the sputum (30%) and spinal cerebral fluid analysis (7%). Duration of treatment ranged from 6 to 13 months and hepatotoxicity
occurred in 3 patients. The patients who died had a significant greater number of rejection episodes and received higher doses of
corticosteroid. In conclusion, the administration of cyclosporine changed the clinical and histopathological pattern of tuberculosis
occurring after renal transplantation.
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INTRODUCTION
Infection is a frequent complication and one of the main causes of
death in patients submitted to renal transplantation, even when
considering the greater availability of diagnostic techniques and the
increased efficacy of antimicrobial agents29. This high frequency of
infection is associated with the immunosuppressive therapy used in
patients who are previously immunocompromised28,36. In this situation,
the incidence of tuberculosis (TB) is 0.5 to 1% in the United States and
1 to 4% in Europe, and can reach about 10% in underdeveloped/
developing countries such as India32,33.
Atypical clinical manifestations of TB are more often found in these
groups of patients6,8,9,23,38,40 and the results are conflicting regarding the
diagnostic value of the cutaneous test (PPD)39. The use of chemotherapy
immediately after transplantation is questioned and the impact of TB
and of antituberculosis drugs on the patient and graft survival has not
been established1. Therefore, we studied the incidence of TB in 1264
renal transplant recipients and analyzed the clinical manifestations and
the diagnostic methods used.
MATERIAL AND METHODS
A retrospective analysis of 1264 renal transplants was carried out at
the Renal Transplant Unit of Hospital São Paulo, UNIFESP, and of
Hospital Dom Silvério Gomes Pimenta, São Paulo, during the period
from June 1976 to March 1996. There were no exclusion criteria and all
renal transplants performed during this period were considered eligible
for the study. Tuberculosis was diagnosed in 30 of the 1264 transplant
patients, with 22 receiving a graft from a living related and 8 from
cadaveric donors. Seventeen patients received the renal graft from living
haploidentical donors, 4 patients from an HLA identical donor and one
from an HLA-distinct donor. The patients who received the transplant
from cadaver donors were selected according to blood ABO compatibility,
negative cross-match against HLA antigens and order of enrollment in
the renal transplant program. The living donors were selected among
family members based on ABO compatibility, HLA compatibility and
negative cross-match against HLA antigens.
The diagnosis of TB was based on the following criteria: demonstration
of alcohol acid-resistant bacilli (AARB) by bacterioscopy or microbial
growth in culture, demonstration of caseous granuloma upon
histopathological examination indicated by the presence of AARB,
adenosine deaminase levels in the cerebrospinal fluid higher than 40 U/L
or in the pleural effusion determined by the calorimetric method of Giusti38.
Tuberculosis was classified, according to the site of isolation of
Mycobacterium tuberculosis, into pulmonary TB when the bacterium
was isolated from sputum and bronchial lavage, and extrapulmonary,
when the bacterium was isolated from other tissues.
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Immunosuppression consisted of a double therapy (azathioprine and
prednisone) for patients transplanted up to 1986. From then on,
cyclosporine was introduced and a triple therapy (azathioprine,
prednisone and cyclosporine) was established. The initial dose of
prednisone was 1.5 to 2 mg/kg/day and was then progressively reduced
to 0.2 mg/kg/day on the 6th month. Azathioprine was administered at a
dose of 1 to 2 mg/kg/day, being adjusted according to total leukocyte
count. The initial cyclosporine A dose was 6 to 8 mg/kg/day, starting on
the first post-transplant day, and adjusted to maintain its trough blood
level between 100 and 250 ng/dL.
All patients with TB were initially treated using a combination of
isoniazid (10 mg/kg), rifampicin (10 mg/kg) and pirazinamide (30 mg/
kg), and subsequent combination with other drugs, when necessary.
Pirazinamide was used only for the first 2 months of treatment while
isoniazid and rifampicin were administered for 6 to 13 months. Hepatic
function was monitored in all patients and hepatotoxicity was diagnosed
when the alanine aminotransferase level increased four times, compared
to the upper normal limit. Two patients had previously received isoniazid
chemoprophylaxis.
The Student t-test was used for comparing continuous variables and
p<0.05 was set as the level of significance.
RESULTS
Tuberculosis was diagnosed in 30 patients (2.4%). Table 1 shows
the demographic and clinical characteristics of the patients. Mean age
was 33 years, ranging from 16 to 60 years. Twenty-one patients were
males, 22 were white and 8 black. Mean weight was 52.7 kg and mean
height 162 cm. The most frequent etiology of chronic renal insufficiency
was chronic glomerulonephritis (70%). Mean time of dialysis was 32.2
months, ranging from 9 to 79 months. Twenty-six patients (86.7%) were
on hemodialysis, 3 (10%) received continuous ambulatory peritoneal
dialysis and one patient was on conservative treatment. Fifteen patients
(50%) belonged to blood group type A, seven (23.3%) to group O, six
(20%) to group B and two (6.7%) to group AB. Only one patient had
received a second renal transplant.
The initial signs and symptoms of the disease are summarized in
Table 2. Fever was the most frequently observed sign (90%), being
generally intermittent and of low degree. Other common symptoms were
weight loss (70%), cough (66.6%), profuse sweating (26.6%) and
anorexia (20%). The lung was involved in 18 patients (60%). In 17 cases
(57%) there was isolated lung involvement, in another case
pleuropulmonary involvement was observed. Isolated pleural
involvement occurred in 2 patients (7%), and in 4 cases other isolated
sites were found to be affected (10%). Disseminated TB was observed
in 6 cases (20%). Radiological chest findings are shown in Table 3.
No extrapulmonary TB was observed in patients receiving the double
immunosuppression scheme, whereas the disseminated form was
observed in 6/17 (35%) patients whose drug regimen included
cyclosporine A (Table 4).
TB was diagnosed between 50 days and 18 years after transplantation,
with four patients (13.3%) being diagnosed during the first 6 months
after transplant, four (13.3%) during the following 6 months, five (16.6%)
Table 1
Demographic, clinical and laboratory characteristics of the 30 patients with TB
Number of patients 30







Weight (kg) 52.7 (± 11.2)
Height (cm) 162 (± 0.04)
Cause of renal failure, N (%)
Chronic glomerulonephritis 21 (70.0)
Systemic arterial hypertension 02 ( 6.6)
Not determined 02 ( 6.6)
Diabetes 01 ( 3.3)
Other 04 (13.3)
Mean time on dialysis (months) 32.2 (9 -79)
Mean follow-up time (months) 48.3 (50 days – 103 months)
First transplant, N (%) 29 (96.6)
Serum creatinine, mg/dl 2.43 (±1.61)
Serum albumin, g/dl 3.65 (±0.04)
Table 3
Radiologic findings of the chest in 26 patients with pleuropulmonary or
disseminated TB
Chest X-ray pattern N %
Pulmonary infiltration 12 46.1
Pulmonary cavitation 06 23.0
Pulmonary condensation 04 15.3
Pleural hemorrhage 02 7.7
Pulmonary infiltration and pleural hemorrhage 01 3.8
Increased mediastinum 01 3.8
Table 2
Signs and symptoms at the time when presenting with TB
N %
Fever 27 90.0




Acute respiratory insufficiency 4 13.3
Lumbar pain 4 13.3
Chest pain 2  6.6
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during the second year, and the remaining 17 cases after this period.
In patients receiving prednisone and azathioprine the manifestations
of TB occurred at a later time. Of the 13 patients receiving the double
scheme, the disease manifested in 11 after the first 3 transplant years
(84.6%). In contrast, among the 17 patients using the triple
immunosuppression scheme, TB occurred in 14 (82.3%) during the first
3 years of transplantation, with the disease being observed in 7 (41.1%)
during the first year.
Primary extrapulmonary involvement occurred in one case before
the end of the first year, and in 9 after the first transplant year. Three
cases of disseminated TB were observed during the first transplant year.
In nine patients (30%) the diagnosis was established by direct staining
of the bacillus in the sputum, and in two by microscopic examination of
cerebrospinal fluid (CSF) smears. Nineteen patients were diagnosed by
biopsy of the affected organs, with 10 cases being diagnosed by
transbronchial biopsy, one of them together with cervical ganglion biopsy,
three by pleural biopsy, one by biopsy of the pericardium and another
Table 6
Post-transplant year of TB diagnosis, immunosuppression scheme and histological presentation of 19 patients submitted to biopsy
IMMUNOSUPPRESSION  SCHEME
TIME AFTER AZA+PRED AZA+PRED+CYA
TRANSPLANT  N(%) HISTOLOGY N(%) HISTOLOGY
1st year 1 (3) 1 exudative 7 (23) 1 granulomatous
3 exudative
2 mixed
2nd year 2 (6) 4 (13) 3 granulomatous
3rd year 3 (10) 1 granulomatous 3 (10) 1 granulomatous
4th year 0 1 (3)
5th year 1 (3) 1 granulomatous 0
6th year 2 (6) 1 granulomatous 1 (3) 1 granulomatous
7th year 0 0
8th year 1 (3) 1 granulomatous 0
9th year 1 (3) 1 granulomatous 1 (3) 1 granulomatous
10th year 3 (10) 1 granulomatous 0
Abbreviations: AZA=azathioprine; PRED=prednisone; CYA=cyclosporine.
Table 4
Tissues affected by TB in the total group of patients and in the groups
receiving the double (azathioprine and prednisone) or triple (azathioprine,
prednisone and cyclosporine) immunosuppression scheme
Localization Double scheme Triple scheme Total
N (%) N (%) N (%)
Lung 10 (77) 07 (41) 17 (57)
Pleura 02 (15) 01 (06) 03 (10)
Extrapulmonary 01 (08) 03 (18) 04 (13)
Disseminated — 06 (35) 06 (20)
TOTAL 13 17 30
Table 5
Method of TB diagnosis in the 30 cases studied
MICROSCOPIC:
AARB in sputum 09




Tracheobronchial + ganglion biopsy 01
Pericardium biopsy 01
Autopsy 04
by biopsy of the cervical ganglion. In four patients TB was diagnosed at
autopsy (Table 5).
The 19 biopsy cases were classified into three histological forms
(Table 6): (a) “exudative” (four cases) characterized by a
polymorphonuclear neutrophilic exudate, rupture of the basic tissue
pattern with necrosis and a high amount of AARB; (b) “granulomatous”
(three cases) characterized by the presence of typical tuberculous
granulomas of the epithelioid form with occasional necrosis, giant cells
and AARB, and (c) “mixed” (two cases) characterized by the presence
of a neutrophilic exudate similar to that observed with the exudative
form, and initial formation of epithelioid granulomas containing AARB.
The exudative and mixed forms were associated with a poor clinical
picture and were only observed when TB occurred during the first post-
transplant year. The granulomatous form was mainly observed after the
first post-transplant year. Of the 7 patients who died, four presented the
granulomatous form, two the exudative form and two the mixed form.
Specific TB therapy consisted of different combinations of drugs, with
isoniazid and rifampicin being used initially in all patients. The other drugs
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used were pirazinamide, ethambutol, streptomycin, ofloxacin,
cyprofloxacin and azithromycin. Five patients showed an acute rejection
episode after the beginning of therapy, three of whom did not recover
renal function and returned to the dialysis program. Four of these patients
used cyclosporine and three presented serum levels below 100 ng/dL,
with a mean value of 91.75 ± 69.24 ng/dL, which was significantly lower
(p<0.05) than that observed for patients who were cured of TB and who
maintained adequate renal function (162.16 ± 139.70 ng/dL). Two other
patients received three different drug combinations due to hepatotoxicity
and/or drug intolerance. The side effects observed were hepatotoxicity (2
cases), peripheral neuropathy (2 cases), hepatitis and neuropathy (1 case),
gastritis, retrobulbar neuritis and labyrinthitis (1 case), and gout (1 case).
Of the 26 patients treated, 22 (84%) were cured, with treatment
duration ranging from 6 to 13 months. Three patients died during
treatment and one patient stopped treatment. No recurrence of the disease
was observed in any case (Table 7).
Although the doses of azathioprine and cyclosporine were higher in
the group of patients who died, they were not significantly different
from those for the group of cured patients. However, the mean prednisone
dose and the number of acute rejection episodes were significantly higher
in the group of patients who died (Table 8).
DISCUSSION
The incidence of TB in patients with chronic renal insufficiency
who receive renal transplant is higher than that observed for the general
population, ranging from 0.5 to 1% in the United States, from 1 to 4% in
Europe, being 3.5% in Saudi Arabia and ranging from 5.7 to 11.8% in
India2,11. This difference between continents reflects the variation in the
incidence of TB in the respective general populations. We observed TB
in 2.4% of transplanted patients, a rate 5 times higher than the prevalence
in the general Brazilian population which is estimated to be 0.5%25,30.
Immunosuppression is the main factor predisposing to infection in
transplant patients, however, it has not yet been established which drugs
result in a higher risk27. SAHN & LAKSHMINARAYAN reported
reactivation of the disease in patients receiving high steroid doses17,31,
and MILLAR & HORNE observed more severe forms of TB in patients
receiving more than 10mg/day of prednisone21. It was also shown that
azathioprine causes dissemination of TB in experimental animals24. Two
studies13,26 did not report any relation between the incidence of
mycobacterial infection and the use of cyclosporine as adjuvant in
immunosuppression.
Among the studied patients diagnosed with TB, the oral prednisone
dose and the number of treated rejection episodes were higher in those
who died than in those who were cured. These results support the idea
that the corticosteroid dose is related to the reactivation and severity of
TB after renal transplantation31. TB was diagnosed in most of our patients
(63.3%) during the first three years after the transplant, with 42% being
diagnosed during the first year, a period during which the steroid dose
was higher. The cases that occurred earlier tended to be more severe and
had a higher mortality, which is in agreement with data reported
previously by other authors1,22. It is tempting to propose that, during this
period, the immunosuppressive effect of previous uremia is still present,
increasing the predisposition to infections3,4,12,15,24. Of the five patients
showing acute rejection during TB treatment, 4 presented blood
cyclosporine levels lower than 100 ng/dL, corresponding to 50% of the
level observed in patients without any alteration of graft function. This
observation may explain the difficulties in finding the ideal dose for
immunosuppression in order to prevent rejection and to minimize
predisposition to opportunistic infections.
The histological pattern of the exudative form was observed during
the first months after transplantation and was found to be associated
with a poor prognosis. The granulomatous form showed a clinical picture
similar to that found in non-immunosuppressed patients and occurred
mainly after the first year of transplantation. One may speculate that
high doses of corticosteroids play an important role in the presentation
of the exudative form, preventing the organization of granulomas18,37.
Fever was a predominant symptom and TB should be suspected in
all transplant patients who present fever of not readily definable etiology,
especially when the lung is affected. The AARB test employed in the
affected system led to the diagnosis of 9 of the 30 patients. Bronchoscopy,
a more aggressive approach, enabled the diagnosis of 11 patients.
Table 8
Dose of immunosuppressive drugs and number of acute rejection episodes in patients with a diagnosis of TB who died compared to those who were cured
Azathioprine Prednisone Cyclosporine Number of acute
(mg/kg/day) (mg/kg/day) (mg/kg/day) rejection episodes
TB – cured (N=22) 1.63 0.41 5.19 1.60
TB – died (N=7) 1.84 0.65* 6.17 2.33**
* p<0.05 and **p<0.001 compared to the cured group.
Table 7
Evolution of the 30 patients with TB diagnosis after renal transplantation
Evolution N %
Cured after treatment – continue with functional graft 17 56.7
Cured after treatment – acute rejection and return
to chronic dialysis 03 10.0
Cured after treatment - acute rejection controlled 02  6.6
Died during treatment 03 10.0
Died without treatment - diagnosis at autopsy 04 13.3
Left medical follow-up 01  3.3
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Pulmonary TB was the most common form of the disease and was
diagnosed in 46% of our patients. QUINIBI et al.27, in a review of 77
cases, found pulmonary lesion in 40% of patients and the disseminated
form of TB in 33%. In a series from Southern India, pulmonary lesion
occurred in 48%, while 26% presented disseminated infection19,34. In
the present study, simple radiologic examination of the thorax was
abnormal in 86% of the patients with pleuropulmonary disease, with
46% presenting a miliary pattern. Mortality was lower when the disease
was limited to the lung, and of the 7 patients who died, 5 had disseminated
TB. Similar results have been reported in other studies35,37.
The initially employed therapeutic regimen for TB did not differ
from that used for the general population, but great caution is
recommended for the combined use of antituberculosis and
immunosuppressive drugs due to the high possibility of
hepatotoxicity7,10,16,20. The side effects of hepatotoxicity, gastric
intolerance and peripheral neuritis led to discontinuation of treatment or
to a change in the therapeutic scheme in 7 of 26 patients treated. Some
authors avoid the use of rifampicin, even when serum cyclosporine levels
are monitored1.
Only 2 of the 30 patients were submitted to chemoprophylaxis after
transplantation. Chemoprophylaxis with isoniazid (300 mg/day) for 12
months is indicated in the following situations5,14: patients living in an
endemic area of TB and with a positive family history, patients with a
previous history of inadequate treatment, patients presenting a PPD test
of more than 10 mm in diameter and patients with pulmonary
calcification, pleural thickening and hilar prominence upon chest X-ray.
The cases presented here illustrate the importance of the diagnosis
of TB in post-transplant patients and its therapeutic difficulties. Fever
was the most common initial symptom, with an earlier and predominantly
extrapulmonary incidence being more common in patients receiving
cyclosporine in combination with azathioprine and prednisone, compared
to those who received the double immunosuppression regimen only. The
histological granulomatous form predominated in the diagnosed cases
after the first year of transplantation, while the exudative and mixed
forms were mainly observed during the first year.
RESUMO
O uso de ciclosporina modifica a apresentação clínica e
histopatológica da tuberculose depois de transplante renal
A tuberculose é uma das mais frequentes infecções oportunistas
encontradas após o transplante renal. A tuberculose foi diagnosticada em
30 de 1.264 pacientes que foram transplantados entre 1976 e 1996 na
unidade de Transplante Renal do Hospital São Paulo – UNIFESP e no
Hospital Dom Silvério Gomes Pimenta em São Paulo. A incidência de
2,4%, é cinco vezes superior à estimada para população geral brasileira. O
diagnóstico foi realizado entre 50 dias a 18 anos após o transplante. Nos
pacientes com esquema duplo de imunossupressão (prednisona e
azatioprina), a manifestação inicial foi mais tardia, sendo que em 11 dos
13 pacientes ocorreu após os primeiros 3 anos de transplante. Enquanto
com esquema tríplice (prednisona, azatioprina e ciclosporina), em 14 de
17 pacientes a doença ocorreu dentro dos primeiros 3 anos. Com esquema
duplo de imunossupressão não houve manifestação de doença extra-
torácica, em contrapartida com esquema tríplice de imunossupressão a
forma de apresentação disseminada ocorreu em 35% dos casos, sendo
mais precoce e mais grave. A febre foi o sintoma clínico principal em 90%
dos casos. O diagnóstico foi confirmado, em 50% (n=15) através da biópsia
dos órgãos envolvidos, em 30% (n=9) através da pesquisa de bacilos álcool
ácido resistentes (BAAR) no escarro, em 7% (n=2) no líquido céfalo-
raquidiano e em 13% (n=4) através de necrópsia. O tempo de tratamento
da tuberculose variou de 6 a 13 meses. A hepatotoxidade relacionada ao
tratamento, ocorreu em três casos. O número de tratamentos prévios de
episódios de rejeição e a dose administrada de corticóides foram maiores
nos pacientes que morreram com este diagnóstico, quando comparados
ao grupo que respondeu ao tratamento. Em conclusão a forma clínica e
histopatológica de apresentação da tuberculose é diferente após o
transplante em pacientes utilizando ciclosporina, sendo a resposta ao
tratamento influenciada pela dose prévia de corticóide.
REFERENCES
1. AGUADO, J.M.; HERRERO, J.A.; GAVALDÁ, J. et al. - Clinical presentation outcome
of tuberculosis in kidney, liver, and heart transplant recipients in Spain.
Transplantation, 63: 1278-1286, 1997.
2. AL-SULAIMAN, M.H.; DHAR, J.M.; AL-HASANI, M.K.; HALEEM, A. & AL-
KHADER, A.A. - Tuberculous interstitial nephritis after kidney transplantation.
Transplantation, 50: 162-164, 1990.
3. ANDREW, O. T.; SCHOENFELD, P. Y.; HOPEWELL, P.C. & HUMPHREYS, M.H. -
Tuberculosis in patients with end-stage renal disease. Amer. J. Med., 68: 59-65,
1980.
4. CENGIZ, K. - Increased incidence of tuberculosis in patients undergoing hemodialysis.
Nephron, 3: 421-424, 1996.
5. CHAVES, A.D.; CUGELL, D.W.; MARKS, C.E. et al. - Preventive treatment of
tuberculosis. Amer. Rev. resp. Dis., 104: 460-465, 1971.
6. CRUZ, N.; MUXÓ, O.R.; BERMÚDEZ, R.H. & DELPHIN, E.A.S. - Pulmonary infection
with M. kansasii in a renal transplant patient. Nephron, 26: 187-188, 1980.
7. DI PERRI, G.; LUZZATI, R.; FORNI, A. et al. – Fatal primary multidrug-resistant
tuberculosis in a heart transplant recipient. Transplant Int., 11: 305-307, 1998.
8. FORSLUND, T.; LAASONE, L.; HÖCKERSTEDT, K.; STENMAN, S. & EDGREN, J.
- Tuberculosis of the colon in a kidney transplant patient. Acta med. scand., 215:
181-184, 1984.
9. GOMEZ, E.; AGUADO, S.; BALTAR, J. et al. – Sterile leukocyturia as a manifestation
of urinary tuberculosis in renal transplant patients. Nephrol. Dial. Tranplant., 13:
1610-1611, 1998.
10. HEBERT, M.F.; ROBERTS, J.P.; PRUEKSARITANONT, T. & BENET, L.Z. -
Bioavailability of cyclosporine with concomitant rifampin administration is markedly
less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther., 52: 453-
457, 1992.
11. HIGGINS, R.M.; CAHN, A.P.; PORTER, D. et al. - Mycobacterial infections after renal
transplantation. Quart. J. Med., 286: 145-153, 1991.
12. JHA, V.; SAKHUJA, V.; GUPTA, D. et al. – Successful management of pulmonary
tuberculosis in renal allograft recipients in a single center. Kidney Int., 56: 1944-
1950, 1999.
13. JOHN, G.T.; VICENT, L.; JEYASEELAN, L.; JACOB, C.K. & SHASTRY, J.C.M. -
Cyclosporine immunosuppression and Mycobacterium infections. Transplantation,
58: 247-248, 1994.

BIZ, E.; PEREIRA, C.A.P.; MOURA, L.A.R.; SESSO, R.; VAZ, M.L.S.; SILVA FILHO, A.P. & PESTANA, J.O.M. – The use of cyclosporine modifies the clinical and histopathological
presentation of tuberculosis after renal transplantation. Rev. Inst. Med. trop. S. Paulo, 42(4): 225-230, 2000.
14. JORDAN, T.J.; LEWIT, E.M. & REICHMAN, L.B. - Isoniazid preventive therapy for
tuberculosis. Amer. Rev. resp. Dis., 144: 1357-1360, 1991.
15. KLEMPERER, J.D.; WANG, J.; HARTMAN, B.J. & STUBENBORD, W.T. –
Mycobacterium tuberculosis infection of a native polycystic kidney following renal
transplantation. Transplantation, 66: 118-120, 1998.
16. KOSELJ, M.; KANDUS, A. & KOVAC, D. - Drug interactions between cyclosporine
and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic
infections. Transplant. Proc., 26: 2823-2824, 1994.
17. LAKSHIMINARAYAN, S. & SAHN, S.A. - Tuberculosis in a patient after renal
transplantation. Tubercle (Edinb.), 54: 72-76, 1973.
18. LLOVERAS, J.; PETERSON, P.K.; SIMMONS, R.L. & NAJARIAN, J.S. -
Mycobacterium infections in renal transplant recipients. Arch. intern. Med., 142:
888-892, 1982.
19. MALHOTRA, K.K.; DASH, S.C.; DHAWAN, I.K.; BHUYAN, U.N. & GUPTA, A -
Tuberculosis and renal transplantation - observations from an endemic area of
tuberculosis. Postgrad. med. J., 62: 359-362, 1986.
20. McALLISTER, W.A.C.; THOMPSON, P.J.; AL-HABET, S.M. & ROGERS, H.J. -
Rifampicin reduces effectiveness and bioavailability of prednisolene. Brit. med. J.,
286: 923-925, 1983.
21. MILLAR, J.W. & HORNE, N.W. – Tuberculosis in immunosuppressed patients. Lancet,
2: 1176-1178, 1979.
22. MÜLLEROVA, M.; PEKAREK, J.; NOUZA, K. et al. - Immunosuppression and
experimental tuberculosis. The effects of immunosuppressive agents and
antilymphocyte serum on the organ dissemination of mycobacteria and on the
development of specific delayed hypersensitivity. Biomedicine, 20: 390-397, 1974.
23. PARK, S.B.; JOO, I.; PARK, Y.I. et al. - Clinical manifestations of tuberculosis in renal
transplant patients. Transplant. Proc., 28: 1520-1522, 1996.
24. PAULA, F.J.; AZEVEDO, L.S.F.; IANHEZ, L.E. et al. - Tuberculosis in patients with
chronic renal failure. Rev. Inst. Med. trop. S. Paulo, 29: 127-130, 1987.
25. PAULA, F.J.; AZEVEDO, L.S.; SALDANHA, L.B.; IANHEZ, L.E. & SABBAGA, E. -
Tuberculosis in renal transplant patients. Rev. Inst. Med. trop. S. Paulo, 29: 268-
275, 1987.
26. PESCHKE, B.; ERNST, W.; GOSSMANN, J. et al. - Antituberculous drugs in kidney
transplant recipients treated with cyclosporine. Transplantation, 56: 236-238, 1993.
27. QUINIBI, W.Y.; AL-SIBAI, M.B.; TAHER, S. et al. - Mycobacterial infections after
renal transplantation-report of 14 cases and review of the literature. Quart. J. Med.,
282: 1039-1060, 1990.
28. RISKA, H. & KUHLBÄCK, B. - Tuberculosis and kidney transplantation. Acta med.
scand., 205: 637-640, 1979.
29. RUBIN, R.H. - Infectious disease complications of renal transplantation. Kidney Int.,
44: 221-236, 1993.
30. SABBAGA, E. - 1.000 transplantes renais - vinte anos de experiência. São Paulo,
1987. (Tese de Livre-Docência - Faculdade de Medicina da Universidade de São
Paulo).
31. SAHN, S.A. & LAKSHMINARAYAN, S. - Tuberculosis after corticosteroid therapy.
Brit. J. Dis. Chest, 70: 195-205, 1976.
32. SAKHUJA, V.S.; JHA, V.; VARMA, P.P.; JOSHI, K. & CHUGH, K.S. - The high incidence
of tuberculosis among renal transplant recipients in India. Transplantation, 61: 211-
215, 1996.
33. SHAHZAD, A.; SOOMRO, S. & RIZVI, A. – Problems of diagnosis and treatment of
tuberculosis following renal transplantation. Transplant. Proc., 29: 3051-3052, 1997.
34. SKOGBERG, K.; RUUTU, P.; TUKIAINEN, P. & VALTONEN, V. - Effect of
immunosuppressive therapy on the clinical presentation and outcome of tuberculosis.
Clin. infect. Dis., 17: 1012-1017, 1993.
35. SPENCE, R.K.; DAFOE, D.C.; RABIN, G. et al. - Mycobacterium infections in renal
allograft recipients. Arch. Surg., 118: 356-359, 1983.
36. STAKE, G. & FLATMARK, A. - Lung complications during immunosuppressive
treatment in renal transplant recipients. Scand. J. resp. Dis., 57: 51-62, 1976.
37. SUNDBERG, R.; SHAPIRO, R.; DARRAS, R. et al. - A tuberculosis outbreak in a renal
transplant program. Transplant. Proc., 23: 3091-3092, 1991.
38. TATO, A.M.; PASCUAL, J.; OROFINO, L. et al. – Laryngeal tuberculosis in renal allograft
patients. Amer. J. Kidney Dis., 31: 701-705, 1998.
39. WALKER, J.F.; CRONIN, C.J.; O’NEILL, S.; MCNULTY, J. & HANSON, J.S. -
Tuberculosis affecting a cadaveric renal allograft. Clin. Nephrol., 17: 262-265, 1982.
40. WANG, A.Y.; LI, P.K.; TO, K.F.; LAI, F.M. & LAI, K.N. – Coexistence of Kaposi´s
sarcoma and tuberculosis in a renal transplant recipient. Transplantation, 66: 115-
118, 1998.
Received: 21 December 1999
Accepted: 17 March 2000
